Analysts/Institutional Investor Meet/Con. Call Updates

IGL/SE/2026-27/44 20th August, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 001 Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Transcript of Q1FY27 Earnings Conference Call Further to our letters bearing no. IGL/SE/2026-27/35, IGL/SE/2026-27/39 & IGL/SE/2026-27/40 dated 6th, 14th & 14th August, 2026 respectively and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the Earnings Conference Call for Q1FY27 held on Friday, 14th August, 2026 is attached. This same is also being hosted on the Company’s website at www.indiaglycols.com. This is for your information and record. Thanking you, Yours truly, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a “India Glycols Limited Q1 FY27 Earnings Conference Call” August 14, 2026 MANAGEMENT: MR. RUPARK SARSWAT – CHIEF EXECUTIVE OFFICER MR. MANOJ KUMAR RAI – EXECUTIVE DIRECTOR AND COO (IGL SPIRITS LIMITED) MR. AKSHAY BANSAL – EXECUTIVE DIRECTOR (ENNATURE BIO PHARMA LIMITED) MR. ANAND SINGHAL – CHIEF FINANCIAL OFFICER MR. S. K. SHUKLA – HEAD, LIQUOR BUSINESS MR. ANKUR JAIN – HEAD, LEGAL AND COMPANY SECRETARY MODERATOR: MR. NITIN AWASTHI – INCRED EQUITIES Page 1 of 16 India Glycols Limited August 14, 2026 Moderator: Ladies and gentlemen, good day, and welcome to India Glycols Limited Q1 FY27 Earnings Call hosted by InCred Equities. As a reminder, all participant lines will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. I now hand the conference over to Mr. Nitin Awasthi. Thank you, and over to you, sir. Nitin Awasthi: Thank you. I would like to thank the management for giving us this opportunity to host the conference call today. From India Glycols management, we have Mr. Rupark Sarswat, Chief Executive Officer; Mr. Manoj Kumar Rai, Executive Director and COO of IGL Spirits Limited; Mr. Akshay Bansal, Executive Director of Ennature Bio Pharma Limited; Mr. Anand Singhal, Chief Financial Officer; Mr. S.K. Shukla, Head of Liquor Business; and Mr. Ankur Jain, Head of Legal and Company Secretary. I would now like to invite Mr. Rupark to initiate the proceedings with his opening remarks, post which we shall open the floor for a Q&A session. Thank you, and over to you, sir. Rupark Sarswat: So thank you very much, and thank you, everybody, for joining us and hope all of you are enjoying your monsoon. And I'm sure a lot of you in Mumbai are waiting to welcome Ganpati. So best wishes to all of you. And now what I intend to do is to start with 2 introductions. First is the gentleman, Mr. Gagan Kwatra, who would be handling Investor Relations for us. He has joined us. I'm sure his presence will make us better prepared to deal with our investors and better answer your questions and be more responsive. He’s had 15 years of work experience in a number of organizations handling Investor Relations and consulting, etcetera, which includes Jubilant Foodworks, LT Foods and prior to that, some consulting assignments that he did with KPMG. The other gentleman I would like to introduce is Mr. Manoj Kumar Rai, who has joined as the Chief Operating Officer for the Spirits and Ethanol business. As you know, with the restructuring, his role becomes very important. So he's a stalwart in the liquor business, and he will help us answer all the difficult questions that you have for this business. He's got 27 years of experience across engineering, consumer goods, entertainment and beverages. He's a B.Tech from IIT Delhi and a Postgraduate in Business Management from IIM Lucknow. He joined from Allied Blenders and Distillers, where he was the Chief Revenue Officer, led 7 consecutive quarters of profitable growth. And he spent 19 years with Pernod Ricard India in multiple roles. And earlier, he's also worked with Marico, Saregama India, Suzler, etcetera. So I've taken the opportunity to introduce them. I'm sure you will have an opportunity to interact with them today and more so going forward. Page 2 of 16 India Glycols Limited August 14, 2026 With that, let me get started on a quick update on the business. And then we can talk a little bit about restructuring, a little bit about the segments and so on. So IGL delivered a very strong start for FY'27 with a double-digit growth in gross revenue, EBITDA and PAT, which was supported by a balanced portfolio and improved profitability. So we've had net revenue of INR1,130 crores, up 9% and a record EBITDA of INR170 crores. So our gross revenue is up 19%, net revenue up 9%, EBITDA up 13% and PAT up 32%. On the business restructuring front, we've got the NCLT approval. Effective date is to be communicated, and we are progressing the actions as per the plan. The business portfolio overall remains well diversified, and you can see that we've been improving our business, making it a better-quality business across businesses and you can see premiumization and margin recovery all across. The Spirits business recorded a revenue of INR361 crores, up 5.3%, EBITDA growth of 14.2%, and the company retained a dominant share in UP and Uttarakhand while benefiting from premium product offerings in these areas. In chemicals, our revenues increased by 20.6% to INR362 crores, driven by growth in multiple areas which include bio-glycols, green solvents, as well as performance chemicals. Bio-Fuel reported a revenue of INR323 crores with EBIT increasing 19% year-on-year to INR27 crores and EBIT margin at 8.4%. Ennature Bio Pharma reported its best-ever quarter with revenue rising 65% year-on-year and EBITDA increasing 188%. So, this growth has been supported by new acquisitions of customers, several nutraceutical launches, expansion of the nicotine business, and in general, improved efficiency. The finance costs for the company declined to INR25 crores in Q1 FY27 from INR45 crores in Q1 FY26, and this is on account of debt reduction which has been supporting the profitable growth as well. Debt levels had reduced during the quarter and debt-to-equity ratio has also improved. And the proposed restructuring that we received NCLT approval is something that we are going to talk about a little more. So, all in all, strong revenue and EBITDA growth, strong margin performance, business restructuring on plan. As far as potable spirits is concerned, the broader theme of premiumization and market leadership continues. On the chemicals front, we have had a good growth across areas, and we’ll talk about the factors subsequently. We recognize that our growth will come from new performance chemicals, which right now is small, but I think the pipeline is strong and we expect it to continue to drive growth year-on-year. As I mentioned, a very strong quarter for Ennature Bio Pharma and good progress with customers etcetera. Just to give you a general thing that people generally ask us about is also the impact of the war. Now, the war has impacted us in multiple ways, some good, some not so good. So, it is both a combination of headwinds and tailwinds for us. As you know, crude spiked to a four-year high, which also [Showing first 8,000 characters — download PDF for full document]